CTXR News and Press, Citius Pharmaceuticals Inc. From 02/14/24

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update PR Newswire Resubmitted LYMPHIR™ Biologics License Application; awaiting PDUFA date Completed enrollment in the Mino-Lok® Pivotal Phase 3 trial C...

2024-02-14 08:45:40 ET More on Citius Pharmaceuticals Seeking Alpha’s Quant Rating on Citius Pharmaceuticals Historical earnings data for Citius Pharmaceuticals Financial information for Citius Pharmaceuticals Read the full article on Seeking Alpha ...

Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma PR Newswire FDA acceptance of the completed resubmission package and issuance of a Pres...

Asics Corporation ADR (ASCCY) is expected to report for quarter end 2023-12-31 W. P. Carey Inc. REIT (WPC) is expected to report $1.16 for Q4 2023 Core Scientific, Inc. (CORZQ) is expected to report for Q4 2023 Essent Group Ltd. (ESNT) is expected to report $1.59 for Q4 2023 SAAB ...

Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors PR Newswire Independent Director nominee expected to be elected at Annual Shareholders' Meeting in March 2024 CRANFORD, N.J. , Jan. 23, 2024 ...

Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters PR Newswire Topline results expected 2Q 2024 Study enrolled a total of 241 patients; 109 catheter failures observed First-and-only antibi...

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update PR Newswire Mino-Lok ® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024 LYMPHIR™ BLA resubmission on track for early 2024 ...

Disco Corporation ADR (DSCSY) is expected to report for Q2 2024 Sonic Foundry Inc. (SOFO) is expected to report for quarter end 2023-09-30 Sono Group N.V. (SEVCQ) is expected to report for quarter end 2023-09-30 Minim Inc (MINM) is expected to report for Q3 2023 Enel Spa ADR (ENLA...

Citius Pharmaceuticals Inc. (CTXR) is expected to report $-0.02 for Q4 2023

Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023 PR Newswire CRANFORD, N.J. , Nov. 9, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company de...